2AB Stock Overview
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Barinthus Biotherapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.08 |
| 52 Week High | US$4.44 |
| 52 Week Low | US$1.50 |
| Beta | -0.44 |
| 1 Month Change | -28.28% |
| 3 Month Change | -7.96% |
| 1 Year Change | 4.52% |
| 3 Year Change | -84.36% |
| 5 Year Change | n/a |
| Change since IPO | -80.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2AB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.3% | -2.2% | 2.5% |
| 1Y | 4.5% | -25.2% | 6.0% |
Return vs Industry: 2AB exceeded the German Biotechs industry which returned -21.2% over the past year.
Return vs Market: 2AB matched the German Market which returned 5.4% over the past year.
Price Volatility
| 2AB volatility | |
|---|---|
| 2AB Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2AB's share price has been volatile over the past 3 months.
Volatility Over Time: 2AB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 130 | Bill Enright | www.barinthusbio.com |
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company’s development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older.
Barinthus Biotherapeutics plc Fundamentals Summary
| 2AB fundamental statistics | |
|---|---|
| Market cap | €84.90m |
| Earnings (TTM) | -€68.08m |
| Revenue (TTM) | €744.42k |
113.3x
P/S Ratio-1.2x
P/E RatioIs 2AB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2AB income statement (TTM) | |
|---|---|
| Revenue | US$802.00k |
| Cost of Revenue | US$44.87m |
| Gross Profit | -US$44.07m |
| Other Expenses | US$29.28m |
| Earnings | -US$73.35m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.88 |
| Gross Margin | -5,495.26% |
| Net Profit Margin | -9,145.51% |
| Debt/Equity Ratio | 0% |
How did 2AB perform over the long term?
See historical performance and comparison